# A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD

> **NCT03104010** · PHASE2 · UNKNOWN · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** Somatropin Injection

## Key facts

- **NCT ID:** NCT03104010
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04
- **Primary completion:** 2022-02
- **Final completion:** 2022-09
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2017-04-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03104010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03104010, "A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03104010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*